The most prominent and well established risk factors for BC are early menarche (beginning of menstrual function) and late age at first childbirth. Breast cancer (BC) can be divided into two categories, sporadic BC and hereditary BC. The genetic changes in sporadic BC are due to external factors while they are inherited in hereditary BC. The inherited mutations are mostly in breast cancer susceptibility genes, specifically, BRCA1and BRCA2 [36] [37] [38] .
Sporadic Breast cancer
Though sporadic breast cancer (SBC) accounts for more than 80% of all BC, very limited information exists about the definite causes. One of the major causes is assumed to be the protein AKT1 serine/threonine kinase, which is resident in the cellular membrane. AKT1
is an oncogene that is regulated by various extracellular factors [39] . In 50% of SBC cases, there is an over-expression of AKT1 protein [40] . AKT1 is associated with BRCA1, and is responsible for the sequestration of BRCA1 in the cytoplasm. This leads Chapter-1 4 to the non-availability of BRCA1 in the nucleus to carry out the DNA repair mechanism [40] . However, its genesis and progression is poorly understood.
Hereditary Breast Cancer
Paul Broca in 1866 was the first person to describe the high prevalence of breast cancer among the members of one family, suggesting linkage to heredity [41] . Hereditary breast cancer (HBC) can be caused by mutations in the group of genes involved in DNA damage repair pathways. These genetic variants are passed from generation to generation. HBC appears to be autosomal dominant in character. Approximately 10-30% of BC is considered to be HBC, whereas only 5-10% of BC cases are discovered with strong hereditary component [42] . The key evidence came after years of efforts made by Hall et al (1990) to identify, by linkage analysis, the breast cancer susceptibility gene. The gene was found on the long arm of human chromosome 17 [1] ; this gene was subsequently named BRCA1 [43] . BRCA1 is known to act as a tumor suppressor gene because in more than 90% of breast cancer cases, this gene is found to be mutated [30, 31] . Also transfection of wild-type BRCA1 into human tumor cell lines results in growth inhibition through cell-cycle arrest. Other known breast cancer susceptibility genes are shown in Figure-1.3, but BRCA1 and BRCA2 are the most frequently mutated in BC.
BRCA1 (breast cancer 1, early onset)
The gene BRCA1 is about 100 kb long and comprises of 24 exons, of which exon one is non-coding while exon four has Alu repeats (transposable element) [44] . BRCA1 encodes a 7.8 kb mRNA that codes for a BRCA1 protein having 1,863 amino acids and a molecular weight of 220 kDa [37] . BRCA1 possesses two nuclear localization signals which help the protein to cross the nuclear membrane easily. BRCA1 is conserved in mammals but not in lower animals [45] . BRCA1-knockout mice die between embryonic day 7.5 and day 13, suggesting that BRCA1 is essential for embryonic development [46, 47] . 
Transcriptional activation by BRCA1
Mammalian gene transcription is a complicated process driven by the molecular complex containing RNA polymerase II, which is a multi-subunit enzyme [54] . RNA polymerase II, along with some general transcriptional factors, assembles at a promoter site (TATA box) and initiates the transcription Figure-1.4 [17] . The transcription process can be stimulated or inhibited by interaction with co-activators or co-repressors respectively. The Chapter-1 6 function of BRCA1 as a transcriptional activator was discovered when the C-terminal of BRCA1 fused with a GAL4 DNA binding domain lead to transcriptional activation in both yeast and mammalian systems [55] . Further, BRCA1-null mice or BRCA1-deficient cells are unable to execute a transcription-coupled DNA repair (TCR) mechanism [56] .
The genes that are actively transcribed undergo TCR. Though there is no direct evidence that BRCA1 can perform TCR, a possible clue is that BRCA1 is co-purified with RNA polymerase II [57]. BRCA1 does not bind to DNA in a sequence-specific manner but, rather binds to abnormal or damaged DNA. The proteins p21 and GADD45 are cellcycle regulators, and the transcriptional activation of their genes is performed by BRCA1 with the help of protein p53, which is also a tumor suppressor gene product [58] . The combination of BRCA1/p53 is also responsible for the activation of cell survival and repair pathways [59].
Figure-1.4: Role of BRCA1 transcriptional regulation. BRCA1 interacts with basic transcription machinery components such as RNA pol-II and RNA helicase A, which ultimately leads to transcriptional activation of downstream genes.
The BRCT domain of BRCA1 interacts with CtIP (CtBP Interacting Protein) and facilitates transcriptional repression [60] . CtIP was originally identified as a binding partner of CtBP that ultimately suppresses transcription by interacting with pRB and p300 proteins [61] . The transcriptional regulation function of BRCA1 depends upon the Chapter-1 7 presence or absence of damaged DNA. In the absence of damaged DNA, BRCA1 interacts with RNA helicase A, which is a part of the RNA polymerase II complex, and helps in transcriptional regulation [57, [62] [63] [64] . In the presence of damaged DNA, the two RING domains of BRCA1-BARD1 complex are known to associate with RNA polymerase II at the transcriptional site blocked due to DNA damage. The exact function of BRCA1-BARD1 complex with respect to RNA polymerase II is unclear, but it may help in the ubiquitination and degradation of RNA polymerase II components. This degradation facilitates the binding of BRCA1 with DNA and also further recruitment of DNA repair proteins [65] . It is believed that TF II, a component of RNA polymerase II complex, can shift to repair mode in stalled RNA polymerase [66].
Role of BRCA1 in DNA repair
Various in-vitro binding assays demonstrate that BRCA1 can be associated with proteins involved in different DNA repair pathways, such as homologous recombination (HR) and non-homologous end joining (NHEJ) [53] . HR is the most accurate double-strand repair mechanism, and the absence of this pathway leads to genomic instability [52] . The first observation that BRCA1 is involved in DNA repair came when Scully et al in 1997
showed that BRCA1 at the DNA damage foci, is associated with RAD51, a DNA repair protein [67] . The RAD51 is a central player in homologous recombination and therefore BRCA1-RAD51 complex repairs the DNA damage by homologous recombination [68] [69]. The MRN complex formed by MRE1, RAD50 and NBS1 is found to interact with BRCA1 and help in HR in DT40 cells [70] . However, the molecular mechanisms by which BRCA1 is associated with RAD50, and how it affects the function of the MRN complex is still not clear Figure- 
BRCA1 and Chromatin Remodelling
The alteration of physical states of chromosomes through post-translational modifications, such as phosphorylation, acetylation and methylation, is known as chromosome remodelling [75] . Several protein complexes such as BASC (BRCA1associated genome-surveillance complex) are involved in this process. BRCA1 is a member of BASC complex, and is also known to interact with the SWI-SNF proteins, which form chromosomal remodelling complexes [76] [77] [78] . There is evidence that BRCA1 can interact with histone deacetylases such as HDAC1 and HDAC2, and may be responsible for the tighter binding of histone with the DNA [79] . Upon chromatin remodelling due to BRCA1, genes such as KU and GADD45 are activated [78] . It is also a known fact that BRCA1 BRCT can interact with proteins like BACH1 that are involved in chromatin remodelling [77].
BRCA1 in Cell-Cycle Check Point Control
The ability to control the precise timing of cell cycle events is essential to repair the damaged DNA prior to cell division [80] . The cellular machinery responsible for cell cycle arrest is called cell-cycle checkpoint. Exposure of cells to ionising radiation results in G2/M checkpoint activation, which allows the cell to repair damaged DNA [80] . Chk1 is a G2/M checkpoint regulator protein and BRCA1 is known to regulate the expression and phosphorylation of Chk1 [81] . The experiment performed by Xu et al [82] has shown that cells that are deficient in the wild-type BRCA1 exhibit a higher mitotic index, compared to the cells that contain wild-type BRCA1. BRCA1 is phosphorylated in the G1 and S phases of the cell cycle. It is also found that cells containing wild-type retinoblastoma (RB) are sensitive for BRCA1-dependent G1 arrest, while RB-/-(null) cells do not show activation [83] . Further evidence shows that BRCA1 interacts not only with hypo-phosphorylated RB, but also with the RbAp46 and RbAp48 proteins and controls the cell-cycle check point [79].
BRCA1 and Apoptosis
When BRCA1 expression is compromised, cells are more sensitive to apoptosis. But when BRCA1 is over-expressed, the PIG3, Bax and PERP, the p53 dependent apoptosis activating genes are down-regulated [59]. BRCA1 does not always inhibit apoptosis; it is Chapter-1 11 also responsible for the activation of interferon γ pathway, which ultimately leads to the up-regulation of genes associated with apoptosis [51].
The multifunctional BRCA1 gene is a subject of extensive studies because mutations in any domains may lead to the formation of breast and ovarian cancer. Studies of genetic signature of BRCA1 domains might foster the way for targeted therapy and genetic counselling.
BRCA1 Domain organization
The BRCA1 
Ring Finger Domain
Chapter-1 Sequence homology analysis has revealed the presence of a Really Interesting New Gene (RING) at the N-terminus of BRCA1 [84] . This domain contains cysteine and histidine residues known to be conserved among Zn-binding proteins of diverse origins and functions. Therefore RING domain of BRCA1 is described as a Zn-binding domain. The ring finger domain is inferred to be crucial for BRCA1 function for the following reasons: i) several clinically important mutations have been found in this region [88] , ii) yeast two-hybrid analysis shows that the ring finger domain is involved in the interactions with the BARD1 and BAP1 proteins, which are crucial for the ubiquitin activity of BRCA1
[89, 90].
Central DNA Binding Domain
The capability of BRCA1 to perform DNA-dependent functions like transcriptional activation and DNA damage signaling is due to its ability to interact with DNA. 
BRCT Domain
The BRca1 
Three dimensional structures of functional domains of BRCA1
Full-length BRCA1 is a 220 kDa protein, and has not been purified in a bacterial system.
There are no reported structures for full-length BRCA1; however, the individual domains have been expressed, purified and structurally characterised by different investigators [10, 96] . The structures of N-terminal RING and C-terminal BRCT domains have been determined using NMR and X-ray diffraction techniques [10, 97].
Structure of RING Domain
The ring finger domain of BRCA1 forms a homodimer in solution, and this homodimer displays ubiquitin-ligase activity. Similarly the RING domain of BARD1 also dimerises and displays ubiquitin-ligase activity. BRCA1 and BARD1 proteins form heterodimers through interactions between their RING domains. Interestingly, the heterodimer displays several fold higher ubiquitin-ligase activity, compared to that of either homodimer. No crystal structure is available for the RING-RING domain of BRCA1 and BARD1 complex. Klevit et al have used NMR to determine the structure (Figure 1.8) of the heterodimer in solution [96] . The complex adopts a fold that is highly conserved in other Chapter-1 14 ring-finger-domain-containing proteins [98, 99] . The ring finger is characterised by eight conserved Cys and His residues arranged in a manner to form two separate Zn 2+ binding sites (site-I and site-II). The BRCA1 RING motif comprises of a short anti-parallel three-stranded β-sheet and two Zn-binding loops along with a central α helix. The BARD1 ring domain structure is similar to BRCA1 ring but lacks the central α helix between the two Zn -binding loops.
Hetero-dimerization is a consequence of interactions at the hydrophobic core of the four helix bundle [96] . The amino acid residues involved in these interactions are shown in ID-1JNX) . The BRCA1 is comprised of two tandem BRCT domains such as N-terminal (1646 N-terminal ( -1736 N-terminal ( ) and C-terminal BRCT domain (1760 N-terminal ( -1863 and a linker domain .
Each BRCT domain is comprised of three α helices and a single four-stranded β sheet. 
BRCT Domain as a Phosphopeptide Interaction Module
The BRCT domain of BRCA1 is known to perform diverse functions by interacting with several phosphorylated proteins. The chemical interactions are with a contiguous stretch of amino acids of consensus sequence pS 0 -X 1 -X 2 -F +3 (the phosphorylated serine at 0 position, X can be any amino acid and phenylalanine residue at +3 position) [106] [107] [108] [109] .
Different binding partners of the BRCA1 BRCT domain have different amino acids at the +2 position [102, 110] , while the residue at +1 position is mostly proline. It has been observed that phosphopeptide interacts with BRCA1-BRCT in a "two-knob" manner. The two "knobs" of interaction are the pS and F residues. The phosphate group of the phosphopeptide interacts with residues at the N-terminal BRCT via salt bridge and hydrogen bonding interactions. The phenylalanine (+3) residue interacts at the hydrophobic pocket in the interface region of N-terminal and C-terminal BRCT repeats.
The conserved residue Arg-1699 plays an important role in recognizing the backbone of Phe (+3) residue through hydrogen bonding. These interactions appear to exist across species as the interacting residues from BRCT domain are conserved on different species.
Till date, crystal structures of five complexes between interacting partners peptides and BRCA1 BRCT have been reported (Table-1.1). From each structure, it has been observed that the association between pSer (0) -X-X Phe (+3) and BRCA1-BRCT is very much conserved [111]. analysed through GST-BRCT pull-down assay, mass spectrometry and western blotting.
Phosphorylated BACH1 was shown to be directly associated with the BRCT domain of The residues of the BRCT domain that contributed to the interaction with phosphopeptide are conserved among BRCA1 orthologs [111, 112] . As shown in Figure-1 (Figure-1.12) . Figure-1.12: Ligplot analysis of BRCA1 BRCT-CtIP complex (PDB ID-1Y98) . The pSer and Phe+3 residues of CtIP peptide (purple bonds)form main interacting centre in the complex.
C) Crystal Structure of BRCA1 BRCT-ACC1
ACC1 is an ATP dependent carboxylase that converts acetyl Co-A to malonyl Co-A for the synthesis of long-chain fatty acids through fatty acid synthase (FAS) [124, 125] .
Different investigators have identified ACC1 as a BRCA1 BRCT domain interacting partner [126] [127] [128] . There are two isozymes of ACC1 i.e. ACC1-α and ACC1-β. ACC1-α is essential for embryonic development because an ACC1-deficient mouse is embryonically lethal. It is found that ACC1-α and FAS levels are up-regulated in many cancers [129] [130] . ACC1 possesses a short-term regulatory mechanism in which active ACC1 can be converted into inactive ACC1 upon phosphorylation at Ser-79 residue.
BRCA1 BRCT is known to interact with phosphorylated ACC1. ACC1 residues (1258-1271) of sequence NH 2 -1258 -DSPPQpSPTFPEAGH-1271 -COOH bind to BRCA1 BRCT with ~3.7 µM binding affinity. The ACC1 has five times less affinity towards BRCT domain compared to BACH1 peptide. The three dimensional structure of the BRCT-ACC1 oligopeptide complex provides atomic-level details of the interaction. Chapter-1 22 The pSer(0) and Phe (+3) binding sites are quite similar to those of BRCA1-BACH1 and BRCA1-CtIP complexes. Figure-1 
D) Crystal Structure of BRCA1 BRCT-ATRIP
The BRCA1-BRCT interacts with ATRIP and BAAT proteins [132, 133] .
Phosphorylation at Ser-239 position in human ATRIP is crucial for interaction with BRCA1 BRCT. When Ser-239 of ATRIP is mutated to Ala, there is abrogation in the complex formation, which results in G2-M checkpoint [132] . The BAAT1 protein is colocalized with ATM and is responsible for auto-phosphorylation of ATM at Ser-1981.
The assembly of BRCA1, ATM and BAAT is essential for DNA double-strand breakinduced ATM activation [133] . Recently, the BRCA1 BRCT domain has been cocrystallized with the ATRIP peptide (NH2-235 PEACpSPQFG 243 -COOH), and the crystal structure has been determined to the high resolution of 1.75Å. In the complex structure, the pSer-239 interacts with N-terminal BRCT pocket while Phe-243 is inserted in the interface pocket (Figure-1.14) . The pSer forms hydrogen bonding with Ser-1656 and Gly-1655, and the Phe-243 forms hydrophobic interactions with Arg-1699, Leu-1701, Phe-1704, Asn-1774, Met-1775, Arg-1835 and Leu-1839. ( Figure-1.15 ). However, one water-mediated hydrogen bond was also observed with Lys-1702. The phenyl ring is inserted into BRCT2 pocket and its carbonyl group forms hydrogen bond with Arg-1699. Even though pSer (0) and Phe (+3) binding is conserved, the whole BRCT-BAAT complex is stabilized additionally by van der Waals interactions and water mediated hydrogen bonding. Figure-1.17 shows alignment of exon 11-13 of BRCA1 from vertebrate species covering a wide spectrum of evolutionary distance. This is the region of BRCA1 which is involved in binding to various proteins during its proper functioning. It is seen that disease-associated mis-sense mutations occur at highly conserved residues, whereas, polymorphisms are in regions of lower conservation. Similarly, experimentally established disease causing mutations of BRCA1 BRCT are also found in the highly conserved region as shown in Figure-1.18 . Figure-1.19 shows locations of the few disease-associated mutations that have been selected for study in the present thesis. To get insights into the mechanisms by which disease associated mutations exert their influence, crystal structures of BRCT mutants with phosphopeptides have been determined by investigators, and these are listed in [10, 141, 142] . For example, Figure-1 .20 shows the M1775K mutant structure overlaid on the structure of wild-type BRCT complexed with the phosphopetide. As can be seen, the side-chain of the lysine-1175 residue is in steric contact with the Phe +3 residue from the phosphopeptide, and this unacceptable steric contact would prevent phosphopeptide binding to the mutant BRCT, thereby adversely affecting the function of BRCA1. Such structural information would help in clinical management of the disease. 
Conclusion
Breast cancer is one of the most common causes of death among women across the globe and in India. Breast cancer can be broadly divided as either sporadic cancer or hereditary breast cancer. The mutations in the breast cancer susceptibility genes, in sporadic breast cancer, are caused by environmental factors, while they are inherited in hereditary breast BRCA1 has two distinct domains in addition to a large unstructured DNA binding central region. These domains are N-terminal RING finger domain and C-terminal BRCT domain. The structural analysis revealed that BRCT domain of BRCA1 acts as a phosphopeptide recognition module. Interactions between a few binding partners and BRCA1-BRCT domain have been structurally characterised, but the possibility that the BRCA1-BRCT domain may have more binding partners is to be expected. The BRCT domain recognizes phosphopeptides that possess the pS-X-X-F motif. The literature indicates that doubly-phosphorylated proteins can also interact with BRCA1 BRCT domain. There is a long list of BRCT domain-containing proteins. The basic function of the BRCT domain is to act as a protein-protein interaction module, but there are a few proteins that do not have reported interacting partners, such as BARD1 BRCT domain. It will be interesting to find potential reasons for the lack of in-vivo binding partners.Most of the breast and ovarian cancer mutations are present in the BRCT and RING finger domains of BRCA1. It is very difficult to distinguish between clinically significant mutations from mere polymorphisms. Mutations occurring in highly conserved region are being suggested as causing. Development of additional tools to reliably distinguish between disease-causing and polymorphic mutations is urgently required in clinical management. Structural studies are also required to understand disease-causing mechanism of BRCA1 BRCT domain mis-sense mutations.
